Next Article in Journal
Chitosan for Gene Delivery and Orthopedic Tissue Engineering Applications
Previous Article in Journal
Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones
Molecules 2013, 18(5), 5594-5610; doi:10.3390/molecules18055594
Article

Development of a New Positron Emission Tomography Tracer for Targeting Tumor Angiogenesis: Synthesis, Small Animal Imaging, and Radiation Dosimetry

1,2,3,4
, 5,6
, 6
, 1
, 1
, 5,6
 and 1,5,*
Received: 7 March 2013; in revised form: 25 April 2013 / Accepted: 10 May 2013 / Published: 15 May 2013
Download PDF [1824 KB, uploaded 18 June 2014]
Abstract: Angiogenesis plays a key role in cancer progression and correlates with disease aggressiveness and poor clinical outcomes. Affinity ligands discovered by screening phage display random peptide libraries can be engineered to molecularly target tumor blood vessels for noninvasive imaging and early detection of tumor aggressiveness. In this study, we tested the ability of a phage-display-selected peptide sequence recognizing specifically bone marrow- derived pro-angiogenic tumor-homing cells, the QFP-peptide, radiolabeled with 64Cu radioisotope to selectively image tumor vasculature in vivo by positron emission tomography (PET). To prepare the targeted PET tracer we modified QFP-phage with the DOTA chelator and radiolabeled the purified QFP-phage-DOTA intermediate with 64Cu to obtain QFP-targeted radioconjugate with high radiopharmaceutical yield and specific activity. We evaluated the new PET tracer in vivo in a subcutaneous (s.c.) Lewis lung carcinoma (LLC) mouse model and conducted tissue distribution, small animal PET/CT imaging study, autoradiography, histology, fluorescence imaging, and dosimetry assessments. The results from this study show that, in the context of the s.c. LLC immunocompetent mouse model, the QFP-tracer can target tumor blood vessels selectively. However, further optimization of the biodistribution and dosimetry profile of the tracer is necessary to ensure efficient radiopharmaceutical applications enabled by the biological specificity of the QFP-peptide.
Keywords: development of new 64Cu radiolabeled peptide; radiopharmaceuticals; targeted radioconjugates; positron emission tomography (PET) imaging; tumor angiogenesis; tumor aggressiveness; responses to therapy development of new 64Cu radiolabeled peptide; radiopharmaceuticals; targeted radioconjugates; positron emission tomography (PET) imaging; tumor angiogenesis; tumor aggressiveness; responses to therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Patterson, C.; Frederick, C.B.; Yuan, H.; Dyer, L.A.; Lockyer, P.; Lalush, D.S.; Veleva, A.N. Development of a New Positron Emission Tomography Tracer for Targeting Tumor Angiogenesis: Synthesis, Small Animal Imaging, and Radiation Dosimetry. Molecules 2013, 18, 5594-5610.

AMA Style

Patterson C, Frederick CB, Yuan H, Dyer LA, Lockyer P, Lalush DS, Veleva AN. Development of a New Positron Emission Tomography Tracer for Targeting Tumor Angiogenesis: Synthesis, Small Animal Imaging, and Radiation Dosimetry. Molecules. 2013; 18(5):5594-5610.

Chicago/Turabian Style

Patterson, Cam; Frederick, C. B.; Yuan, Hong; Dyer, Laura A.; Lockyer, Pamela; Lalush, David S.; Veleva, Anka N. 2013. "Development of a New Positron Emission Tomography Tracer for Targeting Tumor Angiogenesis: Synthesis, Small Animal Imaging, and Radiation Dosimetry." Molecules 18, no. 5: 5594-5610.


Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert